Francisco Gude-Sampedro1,2, Carmen Fernández-Merino2,3, Lucía Ferreiro4,5, Óscar Lado-Baleato6, Jenifer Espasandín-Domínguez1, Xurxo Hervada7, Carmen M Cadarso6, Luis Valdés4,5. 1. Departamento de Epidemiología. Complejo Hospitalario Universitario de Santiago de Compostela. Santiago de Compostela, Spain. 2. Grupo de Métodos de Investigación, Instituto de Investigaciones Sanitarias de Santiago (IDIS), Santiago de Compostela, Spain. 3. Departamento de Medicina Familiar y Comunitaria. Centro de Saúde A Estrada. Pontevedra, Spain. 4. Servicio de Neumología. Complejo Hospitalario Universitario de Santiago de Compostela. Santiago de Compostela, Spain. 5. Grupo Interdisciplinar de Investigación en Neumología. Instituto de Investigaciones Sanitarias de Santiago (IDIS). Santiago de Compostela, Spain. 6. Departamento de Estadística, Análisis Matemático y Optimización. Grupo Interdisciplinar de Bioestadística y Ciencia de Datos Biométricos (GRID-BDS), Universidad de Santiago de Compostela. Santiago de Compostela, Spain. 7. Subdirección de Información sobre Saúde e Epidemioloxía. Dirección Xeral de Saúde Pública, Consellería de Sanidade, Xunta de Galicia. Santiago de Compostela, Spain.
Abstract
BACKGROUND: The prognosis of patients with COVID-19 infection is uncertain. We derived and validated a new risk model for predicting progression to disease severity, hospitalization, admission to intensive care unit (ICU) and mortality in patients with COVID-19 infection (Gal-COVID-19 scores). METHODS: This is a retrospective cohort study of patients with COVID-19 infection confirmed by reverse transcription polymerase chain reaction (RT-PCR) in Galicia, Spain. Data were extracted from electronic health records of patients, including age, sex and comorbidities according to International Classification of Primary Care codes (ICPC-2). Logistic regression models were used to estimate the probability of disease severity. Calibration and discrimination were evaluated to assess model performance. RESULTS: The incidence of infection was 0.39% (10 454 patients). A total of 2492 patients (23.8%) required hospitalization, 284 (2.7%) were admitted to the ICU and 544 (5.2%) died. The variables included in the models to predict severity included age, gender and chronic comorbidities such as cardiovascular disease, diabetes, obesity, hypertension, chronic obstructive pulmonary disease, asthma, liver disease, chronic kidney disease and haematological cancer. The models demonstrated a fair-good fit for predicting hospitalization {AUC [area under the receiver operating characteristics (ROC) curve] 0.77 [95% confidence interval (CI) 0.76, 0.78]}, admission to ICU [AUC 0.83 (95%CI 0.81, 0.85)] and death [AUC 0.89 (95%CI 0.88, 0.90)]. CONCLUSIONS: The Gal-COVID-19 scores provide risk estimates for predicting severity in COVID-19 patients. The ability to predict disease severity may help clinicians prioritize high-risk patients and facilitate the decision making of health authorities.
BACKGROUND: The prognosis of patients with COVID-19infection is uncertain. We derived and validated a new risk model for predicting progression to disease severity, hospitalization, admission to intensive care unit (ICU) and mortality in patients with COVID-19infection (Gal-COVID-19 scores). METHODS: This is a retrospective cohort study of patients with COVID-19infection confirmed by reverse transcription polymerase chain reaction (RT-PCR) in Galicia, Spain. Data were extracted from electronic health records of patients, including age, sex and comorbidities according to International Classification of Primary Care codes (ICPC-2). Logistic regression models were used to estimate the probability of disease severity. Calibration and discrimination were evaluated to assess model performance. RESULTS: The incidence of infection was 0.39% (10 454 patients). A total of 2492 patients (23.8%) required hospitalization, 284 (2.7%) were admitted to the ICU and 544 (5.2%) died. The variables included in the models to predict severity included age, gender and chronic comorbidities such as cardiovascular disease, diabetes, obesity, hypertension, chronic obstructive pulmonary disease, asthma, liver disease, chronic kidney disease and haematological cancer. The models demonstrated a fair-good fit for predicting hospitalization {AUC [area under the receiver operating characteristics (ROC) curve] 0.77 [95% confidence interval (CI) 0.76, 0.78]}, admission to ICU [AUC 0.83 (95%CI 0.81, 0.85)] and death [AUC 0.89 (95%CI 0.88, 0.90)]. CONCLUSIONS: The Gal-COVID-19 scores provide risk estimates for predicting severity in COVID-19patients. The ability to predict disease severity may help clinicians prioritize high-risk patients and facilitate the decision making of health authorities.
Authors: M Woodhead; F Blasi; S Ewig; J Garau; G Huchon; M Ieven; A Ortqvist; T Schaberg; A Torres; G van der Heijden; R Read; T J M Verheij Journal: Clin Microbiol Infect Date: 2011-11 Impact factor: 8.067
Authors: Ramón Rabuñal; Roi Suarez-Gil; Rafael Golpe; Mónica Martínez-García; Raquel Gómez-Méndez; Eva Romay-Lema; Antía Pérez-López; Ana Rodríguez-Álvarez; Mercedes Bal-Alvaredo Journal: Telemed J E Health Date: 2020-06-04 Impact factor: 3.536
Authors: Karel G M Moons; Douglas G Altman; Johannes B Reitsma; John P A Ioannidis; Petra Macaskill; Ewout W Steyerberg; Andrew J Vickers; David F Ransohoff; Gary S Collins Journal: Ann Intern Med Date: 2015-01-06 Impact factor: 25.391
Authors: Laure Wynants; Ben Van Calster; Gary S Collins; Richard D Riley; Georg Heinze; Ewoud Schuit; Marc M J Bonten; Darren L Dahly; Johanna A A Damen; Thomas P A Debray; Valentijn M T de Jong; Maarten De Vos; Paul Dhiman; Maria C Haller; Michael O Harhay; Liesbet Henckaerts; Pauline Heus; Michael Kammer; Nina Kreuzberger; Anna Lohmann; Kim Luijken; Jie Ma; Glen P Martin; David J McLernon; Constanza L Andaur Navarro; Johannes B Reitsma; Jamie C Sergeant; Chunhu Shi; Nicole Skoetz; Luc J M Smits; Kym I E Snell; Matthew Sperrin; René Spijker; Ewout W Steyerberg; Toshihiko Takada; Ioanna Tzoulaki; Sander M J van Kuijk; Bas van Bussel; Iwan C C van der Horst; Florien S van Royen; Jan Y Verbakel; Christine Wallisch; Jack Wilkinson; Robert Wolff; Lotty Hooft; Karel G M Moons; Maarten van Smeden Journal: BMJ Date: 2020-04-07
Authors: Sara S Jdiaa; Razan Mansour; Abdallah El Alayli; Archana Gautam; Preston Thomas; Reem A Mustafa Journal: J Nephrol Date: 2022-01-11 Impact factor: 3.902
Authors: Nicola Caranci; Chiara Di Girolamo; Letizia Bartolini; Daniela Fortuna; Elena Berti; Stefano Sforza; Paolo Giorgi Rossi; Maria Luisa Moro Journal: Int J Environ Res Public Health Date: 2021-12-15 Impact factor: 3.390
Authors: Nicolás Francisco Fernández-Martínez; Rocío Ortiz-González-Serna; Álvaro Serrano-Ortiz; Mario Rivera-Izquierdo; Rafael Ruiz-Montero; Marina Pérez-Contreras; Inmaculada Guerrero-Fernández de Alba; Álvaro Romero-Duarte; Inmaculada Salcedo-Leal Journal: Int J Environ Res Public Health Date: 2021-08-26 Impact factor: 3.390